Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules

Immunological Investigations

Volumn 39, Issue 1, 2010, Pages 27-38

  Araste, Julia Maryam ^a   Sarvestani, Eskandar Kamali ^a,b   Aflaki, Elham ^b,c   Amirghofran, Zahra ^a,b,d  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Department of Internal Medicine ^*

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

AntiSSA La.; AntiSSA Ro; Fas; Fas ligand; Polymorphism; Systemic lupus erythematosus

Indexed keywords

FAS ANTIGEN; FAS LIGAND; LA ANTIBODY; RO ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLELE; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; ULTRAVIOLET B RADIATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD95; APOPTOSIS; DNA MUTATIONAL ANALYSIS; FAS LIGAND PROTEIN; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IRAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 75149141291     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820130903401736     Document Type: Article

References (28)

1. Al-Maini, M.H., Mountz, J.D., Al-Mohri, H.A., El-Ageb, E.M., Al-Riyami, B.M., Svenson, K.L., Zhou, T., Richens, E.R. (2000). Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus 9:132-139.
2. Behrmann, I., Walczak, H., Krammer, P.H. (1994). Structure of the human APO-1 gene. Eur. J. Immunol. 24:3057-3062.
3. Bolstad, A.I., Wargelius, A., Nakken, B., Haga, H.J., Jonsson, R. (2000). Fas and Fas ligand gene polymorphisms in primary Sjogren's syndrome. J. Rheumatol. 27:2397-2405.
4. Cheng, J., Liu, C., Koopman, W.J., Mountz, J.D. (1995). Characterization of human Fas gene. Exon/intron organization and promoter region. J. Immunol. 154: 1239-1245.
5. Cheng, J., Zhou, T., Liu, C., Shapiro, J.P., Brauer, M.J., Kiefer, M.C., Barr, P.J, Mountz, J.D. (1994). Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762.
6. Danchenko, N., Satia, J.A., Anthony, M.S. (2006). Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 15:308-318.
7. Geleijns, K., Laman, J.D., van Rijs, W., Tio-Gillen, A.P., Hintzen, R.Q., van Doorn, P.A., Jacobs, B.C. (2005). Fas polymorphisms are associated with the presence of antiganglioside antibodies in Guillain-Barre syndrome. J. Neuroimmunol. 161:183-189.
8. Hao, J.H., Ye, D.Q., Zhang, G.Q., Liu, H.H., Dai, H., Huang, F., Pan, F.M., Su, H., Dong, M.X., Chen, H., Wang, Q., Zhang, X.J. (2006). Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese. Arch. Dermatol. Res. 297:329-332.
9. Hochberg, M.C. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arth. Rheum. 40:1725.
10. Horiuchi, T., Nishizaka, H., Yasunaga, S., Higuchi, M., Tsukamoto, H., Hayashi, K., Nagasawa, K. (1999). Association of Fas/APO-1 gene polymorphism with systemic lupus erythematosus in Japanese. Rheumatology 38:516-520.
11. Huang, Q.R., Danis, V., Lassere, M., Edmonds, J., Manolios, N. (1999). Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology 38:645-651
12. Huang, Q.R., Manolios, N. (2000). Investigation of the-1377 polymorphism on the Apo-1/Fas promoter in systemic lupus erythematosus patients using allele-specific amplification. Pathology 32:126-130.
13. Inazawa, J., Itoh, N., Abe, T., Nagata, S. (1992). Assignment of the human Fas antigen gene (FAS) to 10q24.1. Genomics 14:821-822.
14. Kanemitsu, S., Ihara, K., Saifddin, A., Otsuka, T., Takeuchi, T., Nagayama, J., Kuwano, M., Hara, T. (2002). A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J. Rheumatol. 29:1183-1188.
15. Knipping, E., Debatin, K.M., Stricker, K., Heilig, B., Eder, A., Krammer, P.H. (1995). Identification of soluble APO-1 in supernatants of human B-and T-cell lines and increased serum levels in B-and T-cell leukemias. Blood 85:1562-1569.
16. Lee, Y.H., Kim, Y.R., Ji, J.D., Sohn, J., Song, G.G. (2001). Fas promoter-670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus. J. Rheumatol. 28:2008-2011.
17. Look, D.C., Pelleticr, M.R., Tidwell, R.M., Roswit, W.T., Holtzman, M.J. (1995). STAT1 depends on transcriptional synergy with SP1. J. Biol. Chem. 170:30264-30267.
18. Miller, S.A., Dykes, D.D., Polesky, H.F. (1998). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 11(16):1215.
19. Mullighan, C.G., Heatley, S., Lester, S., Rischmueller, M., Gordon, T.P., Bardy, P.G. (2004). Fas gene promoter polymorphisms in primary Sjogren's syndrome. Ann. Rheum. Dis. 63:98-101.
20. Nolsue, R.L., Kelly, J.A., Pociot, F., Moser, K.L., Kristiansen, O.P., Mandrup-Poulsen, T., Harley, J.B. (2005). Functional promoter haplotypes of the human FAS gene are associated with the phenotype of SLE characterized by thrombocytopenia. Genes Immun. 6:699-706.
21. Nolsue, R.L., Kristiansen, O.P., Larsen, Z.M., Johannesen, J., Pociot, F., Mandrup-Poulsen, T. (2002). Complete mutation scan of the human Fas ligand gene: linkage studies in Type I diabetes mellitus families. Diabetologia 45:134-139.
22. Pinti, M., Troiano, L., Nasi, M., Moretti, L., Monterastelli, E., Mazzacani, A., Mussi, C., Ventura, P., Olivieri, F., Franceschi, C., Salvioli, G., Cossarizza, A. (2002). Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians. Cell. Death. Differ. 9:431-438.
23. Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I.A., Debatin, K.M., Fischer, A., de Villartay, J.P. (1995). Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347-1349.
24. Rudert, F., Visser, E., Forbes, L., Lindridge, E., Wang, Y., Watson, J. (1995). Identification of a silencer, enhancer and basal promoter region in the human CD95 (Fas/ APO-1) gene. DNA Cell. Biol. 14:931-937.
25. Sibley, K., Rollinson, S., Allan, J.M., Smith, A.G., Law, G.R., Roddam, P.L., Skibola, C.F., Smith, M.T., Morgan, G.J. (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 63:4327-4330.
26. Suzuki, N., Ichino, M., Mihara, S., Kaneko, S., Sakane, T. (1998) Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 41:344-353.
27. Takahashi, T., Tanaka, M., Brannan, C., Jenkins, N.A., Copeland, N.G., Suda, T., Nagata, S., Cheng, J., Zhou, T., Liu, C., Shapiro, J.P., Brauer, M.J., Kiefer, M.C., Barr, P.J., Mountz, J.D. (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969-976.
28. Van Veen,T., Kalkers, N.F., Crusius, J.B., van Winsen, L., Barkhof, F., Jongen, P.J., Peña, A.S., Polman, C.H., Uitdehaag, B.M. (2002). The FAS-670 polymorphism influences susceptibility to multiple sclerosis. J. Neuroimmunol. 128:95-100.